Lenalidomide Upregulates CXCR4 on CD34+ Hematopoietic Cells Resulting In Increased Binding to Bone Marrow Niche and Inhibiting Mobilization Into Peripheral Blood In Multiple Myeloma Patients
Abstract. Abstract 4079Background:. In multiple myeloma (MM), lenalidomide has impressive clinical activity in patients with both relapsed/refractory and newly